Metagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference
20 Septembre 2024 - 1:15AM
Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines
company committed to developing curative therapeutics for patients
using its proprietary gene editing toolbox, today announced that
company management will participate in the following events at
Chardan's 8th Annual Genetic Medicines Conference:
- Fireside chat on Monday, September 30, 2024, 2:30 PM - 3:00 PM
ET with Brian Thomas, CEO and Founder, Dr. Sarah Noonberg, CMO, and
Alan Brooks, SVP Preclinical.
- Panel discussion titled, “Genome editing for gene insertion and
gene correction - where we are and what's next,” on Monday,
September 30, 2024, 5:00 PM - 5:30 PM ET with Brian C. Thomas, CEO
and Founder.
A live conference webcast of the fireside chat will be available
in the investor section of the company's website at
https://ir.metagenomi.co/. Replays for both events will be
available for a limited time at the same address.
About Metagenomi
Metagenomi is a precision genetic medicines company committed to
developing curative therapeutics for patients using its
proprietary, comprehensive metagenomics-derived toolbox. Metagenomi
is harnessing the power of metagenomics, the study of genetic
material recovered from the natural environment, to unlock four
billion years of microbial evolution to discover and develop a
suite of novel editing tools capable of correcting any type of
genetic mutation found anywhere in the genome. Its comprehensive
genome editing toolbox includes programmable nucleases, base
editors, and RNA and DNA-mediated integration systems (including
prime editing systems and clustered regularly interspaced short
palindromic repeat associated transposases). Metagenomi believes
its diverse and modular toolbox positions the company to access the
entire genome and select the optimal tool to unlock the full
potential of genome editing for patients. For more information,
please visit https://metagenomi.co.
Cautionary Note Regarding Forward‐Looking
Statements
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, each as
amended. Such statements, which are often indicated by terms such
as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “will,” “would”
and similar expressions, include, but are not limited to, any
statements relating to our growth strategy and product development
programs, including the timing of and our ability to conduct
IND-enabling studies, make regulatory filings such as INDs,
statements concerning the potential of therapies and product
candidates, including our development candidate, MGX-001,
statements concerning the timing of data presentations and
publications, and any other statements that are not historical
facts. Forward looking statements are based on management’s current
expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial
condition, and stock value. Factors that could cause actual results
to differ materially from those currently anticipated include:
risks relating to our growth strategy; our ability to obtain,
perform under, and maintain financing and strategic agreements and
relationships; risks relating to the results of research and
development activities; risks relating to the timing of starting
and completing clinical trials; uncertainties relating to
preclinical and clinical testing; our dependence on third party
suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need
for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks
described in “Risk Factors,” in our most recent Form 10-K and our
most recent 10-Qs on file with the Securities and Exchange
Commission. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as required by law,
and we claim the protection of the safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform
Act of 1995.
Investor Contact:Simon Harnest - CIO, SVP Investor
Relationssimon@metagenomi.co
Media Contact:Ashlye Hodge - Communications
Managerashlye@metagenomi.co
Metagenomi (NASDAQ:MGX)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Metagenomi (NASDAQ:MGX)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024